DRUG

Conviction 4HealthcareScan · Thu, Sep 24, 2026

Bright Minds Biosciences Inc. (DRUG) closed at $52.94 (-8.60%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 25, RS Rating 53, -44.9% from its 52-week high, -36.6% year to date. Sector: Healthcare · Biotechnology.

DRUG$52.94-8.60%

ResistanceSupportVol 14

Vol MA14 84.33K

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

BRIGHT MINDS BIOSCIENCES INC.Biotechnologywww.brightmindsbio.com ↗

Price52.94

Change-8.60%

Gap-1.10%

Rel volume—

Avg volume83.31K

Avg $ vol5.34M

SMA 2064.53

SMA 5071.94

SMA 20077.53

Price vs 50-26.42%

Price vs 200-31.72%

MA stackbearish

50/200 cross—

Supertrenddown · 65.43

RSI (14)25

MACD hist-0.77

MACD cross—

Stoch %K / %D0 / 10

ADX (14)36

+DI / −DI10 / 41

RSI divergence—

MACD divergence—

ATR %6.58%

ADR %4.63%

52w high95.99

52w low50.83

From 52w high-44.85%

Above 52w low+4.15%

New 52w highNo

SqueezeOff

Bollinger width34.34%

%B-0.02

Donchian pos0.17%

Donchian high76.80

Donchian low52.90

AVWAP (52w high)76.65

vs AVWAP high-30.93%

AVWAP (52w low)74.65

vs AVWAP low-29.08%

OBV trendDown

Chaikin MF (20)-0.38

Today vs 20d—

Avg vol (14d)84.33K

Avg vol (20d)83.31K

Avg $ vol (20d)5.34M

Market cap519.45M

RS Rating53 / 99

RS 3m (vs SPY)-21.30%

RS 6m (vs SPY)-45.37%

RS line new highNo

Trend template1/8

Technical rank8.5

1 week-13.99%

1 month-33.40%

3 months-16.81%

6 months-28.56%

1 year+5.67%

YTD-36.57%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target181.62

Target upside243.06%

Analyst ratingBuy

Institutional107.85%

Ent. value519.45M

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out9.73M

Employees25

ListedMon, Mar 8, 2021

Free float7.2M

Float %74.0%

Short interest893.57K

Days to cover7.1d

Short volume30.3%

Squeeze score50 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.17 vs −$1.39

Last surprise+87.8% beat

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank8.5 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance85.00

Support64.30

Days since event—

Candle confirm—

Congress activity

Disclosed STOCK Act trades in DRUG

All disclosures →

No recent disclosed trades by Congress in DRUG. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DRUG

No recent insider (Form 4) filings in DRUG. Insiders must file within two business days of a trade.

SEC filings

EDGAR filings in DRUG · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.